Sotatercept: A First-In-Class Activin Signaling Inhibitor for Pulmonary Arterial Hypertension [0.03%]
索塔西普：用于肺动脉高压的同类第一活性抑制信号抑制剂
Aimon C Miranda,Cyrille K Cornelio,Bao Anh C Tran et al.
Aimon C Miranda et al.
Objective: The objective of the study is to review the characteristics, efficacy, safety, and clinical relevance of sotatercept in pulmonary arterial hypertension (PAH). Data Sources: A literature search containing search terms related to s...
Comparison of 12- to 24-Hour Versus 72-Hour Intravenous Terlipressin in Patients With Acute Esophageal Variceal Bleeding: A Systematic Review and Meta-analysis [0.03%]
12至24小时与72小时静脉内使用特利肝素治疗急性食管曲张出血患者的比较：系统性回顾和meta分析
Mohammad Al Hayek,Bisher Sawaf,Shahem Abbarh et al.
Mohammad Al Hayek et al.
Objective: To compare the efficacy and safety of 12-24 hours versus 72 hours of intravenous terlipressin therapy in patients with acute esophageal variceal bleeding (AVB). Data sources: A systematic search was conducted using PubMed, Scopus...
State Variation in Uptake of Pharmacy-Based CLIA-Waived Testing: Impact of Laws and Regulations [0.03%]
基于药房的CLIA豁免检验项目的采纳情况及其与立法和监管的关系
Alex J Adams,Donald G Klepser,Michael E Klepser
Alex J Adams
Background: Community pharmacies have grown to be an increasingly important provider of CLIA-waived tests, just second to physician offices as the venue with the most waivers. Yet, individual variation is still observed across states with r...
Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases [0.03%]
慢性炎症性风湿病患者从阿达木单抗类似药MSB11022转换为阿达木单抗类似药GP2017后的持久性研究
Joaquín Borrás-Blasco,Alejandro Valcuende-Rosique,Silvia Cornejo et al.
Joaquín Borrás-Blasco et al.
Objective: Provide real-world data on switching from adalimumab biosimilar MSB11022 to GP2017 related to persistence, adherence, and safety in adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthr...
Risk of Tendon Injury in Patients Treated With Fluoroquinolone (FQ) Vs Non-Fluoroquinolone Antibiotics for Urinary Tract Infection (UTI) [0.03%]
尿路感染患者使用氟喹诺酮类和非氟喹诺酮类抗菌药物治疗后的肌腱损伤风险：倾向评分匹配的回顾性队列研究
Virginia H Fleming,Jianing Xu,Xianyan Chen et al.
Virginia H Fleming et al.
Background: Fluoroquinolones (FQs) are associated with potential tendon injury but comparative risk versus other antibiotic (non-FQ) options for the same indication has rarely been evaluated. ...
Impact of Nonmedical Switches From Reference Infliximab to Biosimilars on Disease Control Within a Rheumatology Practice [0.03%]
风湿科实践中的参考英夫利昔单抗非医学转用生物仿制药对疾病控制的影响
Marta Jankowska,Krista Dessureault,Julie MacDougall et al.
Marta Jankowska et al.
Background: Infliximab is an anti-tumor necrosis factor agent used to treat rheumatologic disease. Evidence on the safety of switching to biosimilars and the associated risk factors for flares/loss of disease control within rheumatology is ...
Effectiveness and Safety of Sodium-Glucose Cotransporter-2 Inhibitor Continuation in Patients With Type 2 Diabetes and Late-Stage Chronic Kidney Disease [0.03%]
钠葡萄糖共转运蛋白-2抑制剂用于2型糖尿病合并晚期慢性肾脏病患者的有效性和安全性
Olivia Denny,Nicole P Albanese,Calvin J Meaney et al.
Olivia Denny et al.
Background: Expansion of sodium-glucose cotransporter-2 inhibitor (SGLT2i) use in chronic kidney disease (CKD) prompted a pragmatic study of their safety and effectiveness in patients with type 2 diabetes mellitus (T2DM) and late-stage CKD....
Elizabeth Lemanske,Justin Zimmerman,Paul Dobry et al.
Elizabeth Lemanske et al.
Background: Heparin is a high-risk medication with significant variability across patients. Systematic data analysis can help hospitals improve heparin management, ensuring safe and effective anticoagulation. An opportunity exists to create...
An Overview of Randomized Controlled Trials Examining Prescription and Nonprescription Pharmacological Interventions for Moderate to Severe Traumatic Brain Injury [0.03%]
随机对照试验综述：中重度创伤性脑损伤的处方和非处方药物干预措施
Sarvenaz Mehrabi,Cecilia Flores-Sandoval,Robert Teasell et al.
Sarvenaz Mehrabi et al.
Objective: To characterize randomized controlled trials (RCTs) of pharmacological interventions (prescription medications, nonprescription medications, and supplements) for the management of moderate to severe traumatic brain injury (MSTBI)...